BRIEF-Shanghai Junshi Biosciences Says Toripalimab In Combination With Axitinib Granted Orphan-Drug Designation By US FDA

March 27 (Reuters) - Shanghai Junshi Biosciences Co Ltd :

* SHANGHAI JUNSHI BIOSCIENCES - TORIPALIMAB IN COMBINATION WITH AXITINIB FOR TREATMENT OF MUCOSAL MELANOMA GRANTED ORPHAN-DRUG DESIGNATION BY US FDA Source text for Eikon: Further company coverage: